Skip to main content
. 2018 Nov 21;24(43):4920–4927. doi: 10.3748/wjg.v24.i43.4920

Table 3.

Univariate analysis for the factors associated with posttransplant metabolic syndrome

Variable OR (95%CI) P value
Age 1.26 (0.48-3.31) 0.642
Male 1.25 (0.34-4.64) 0.735
Smoking 1.33 (0.45-3.92) 0.605
Alcohol 2.44 (0.83-7.13) 0.104
HBV 0.92 (0.34-2.47) 0.865
HCV 0.43 (2.25-13.6) 0.408
BMI 7.69 (1.75-33.8) 0.007
Pre-LT diabetes mellitus 2.19 (0.64-7.55) 0.214
Pre-LT hypertension 1.62 (0.17-15.3) 0.674
Pre-LT dyslipidemia 2.17 (0.27-17.5) 0.469
Donor age 2.42 (0.67-8.74) 0.178
Donor BMI 1.91 (0.37-9.90) 0.443
WIT 1.21 (1.04-1.41) 0.014
CIT 0.95 (0.69-1.31) 0.741
Steroid-free protocol for HCC 0.35 (0.10-1.24) 0.065
Tacrolimus use ≥ 24 mo 1.77 (0.39-4.01) 0.591
Cyclosporine use ≥ 24 mo 1.30 (0.50-3.40) 0.591
MMF use ≥ 24 mo 1.05 (0.39-2.83) 0.920
Acute graft rejection 1.69 (0.43-6.61) 0.450
Biliary complication 0.48 (0.17-2.28) 0.467
Acute kidney injury 4.72 (1.60-14.0) 0.005
Hyperuricemia 6.95 (2.54-19.0) < 0.001

OR: Odds ratio; CI: Confidence interval; HBV: Hepatitis B virus; HCV: Hepatitis C virus; BMI, Body mass index; WIT: Warm ischemia time; CIT; Cold ischemia time; LT: Liver transplantation; HCC: Hepatocellular carcinoma; MMF: Mycophenolate mofetil.